GET73 Prevents Ethanol-Induced Neurotoxicity in Primary Cultures of Rat Hippocampal Neurons.
OBJECTIVE
N-[(4-trifluoromethyl) benzyl] 4-methoxybutyramide (GET73) may be considered a promising therapeutic agent for the treatment of alcohol use disorders. The compound displayed anti-alcohol and anxiolytic properties in rat. In the present study, an in vitro experimental model of chronic ethanol treatment was used to investigate the ability of the compound to counteract the ethanol-induced neurotoxicity.


METHODS
Primary cultures of rat hippocampal neurons were exposed to ethanol (75 mM; 4 days) and the neuroprotective effects of GET73 were assessed by evaluating cell viability, cell morphology, glutamate levels and reactive oxygen species production.


RESULTS
The exposure to ethanol induced a reduction of cell viability, an alteration of cytoskeleton, a decrease in extracellular glutamate levels and an increase of reactive oxygen species production. The addiction of GET73 (1 and 10 µM) 1 h before and during chronic ethanol exposure prevented all the above ethanol-induced effects. Based on the proposed GET73 mechanism of action, the effects of mGlu5 receptor negative allosteric modulator, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), on ethanol-induced reduction of cell viability were also assessed. The results indicated that the addiction of MPEP (100 µM) 1 h before and during chronic ethanol exposure prevented the ethanol-induced cell viability reduction.


CONCLUSIONS
The present findings provide the first evidence that GET73 shows a neuroprotective role against ethanol-induced neurotoxicity in primary cultures of rat hippocampal neurons. Together with previous findings, these results suggest that GET73 possesses multifaceted properties thus lending further support to the significance of developing GET73 as a therapeutic tool for use in the treatment of alcohol use disorders.
Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy IRET Foundation, Ozzano Emilia, Bologna, Italy.
Maria C
MC
Tomasini
Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Andrea C
AC
Borelli
IRET Foundation, Ozzano Emilia, Bologna, Italy Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Sarah
S
Beggiato
IRET Foundation, Ozzano Emilia, Bologna, Italy Department of Medical Sciences, University of Ferrara, Ferrara, Italy LTTA Centre, University of Ferrara, Ferrara, Italy.
Sergio
S
Tanganelli
Laboratorio Farmaceutico CT, Sanremo, Italy.
Antonella
A
Loche
Laboratorio Farmaceutico CT, Sanremo, Italy.
Roberto
R
Cacciaglia
Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy IRET Foundation, Ozzano Emilia, Bologna, Italy LTTA Centre, University of Ferrara, Ferrara, Italy frl@unife.it.
Luca
L
Ferraro
IRET Foundation, Ozzano Emilia, Bologna, Italy Department of Medical Sciences, University of Ferrara, Ferrara, Italy LTTA Centre, University of Ferrara, Ferrara, Italy.
Tiziana
T
Antonelli
D000813:Anilides / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D002478:Cells, Cultured; D000431:Ethanol / Q000633:toxicity*; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism
D000813:Anilides; C522244:N-(4-trifluoromethylbenzyl)-4-methoxybutanamide; D018696:Neuroprotective Agents; D017382:Reactive Oxygen Species; D000431:Ethanol